Adverum Cost Of Revenue vs Non Operating Income Net Other Analysis
ADVM Stock | USD 5.74 0.15 2.55% |
Adverum Biotechnologies financial indicator trend analysis is way more than just evaluating Adverum Biotechnologies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adverum Biotechnologies is a good investment. Please check the relationship between Adverum Biotechnologies Cost Of Revenue and its Non Operating Income Net Other accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.
Cost Of Revenue vs Non Operating Income Net Other
Cost Of Revenue vs Non Operating Income Net Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adverum Biotechnologies Cost Of Revenue account and Non Operating Income Net Other. At this time, the significance of the direction appears to have strong relationship.
The correlation between Adverum Biotechnologies' Cost Of Revenue and Non Operating Income Net Other is 0.67. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Non Operating Income Net Other in the same time period over historical financial statements of Adverum Biotechnologies, assuming nothing else is changed. The correlation between historical values of Adverum Biotechnologies' Cost Of Revenue and Non Operating Income Net Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Adverum Biotechnologies are associated (or correlated) with its Non Operating Income Net Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Operating Income Net Other has no effect on the direction of Cost Of Revenue i.e., Adverum Biotechnologies' Cost Of Revenue and Non Operating Income Net Other go up and down completely randomly.
Correlation Coefficient | 0.67 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Cost Of Revenue
Cost of Revenue is found on Adverum Biotechnologies income statement and represents the costs associated with goods and services Adverum Biotechnologies provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Non Operating Income Net Other
Most indicators from Adverum Biotechnologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adverum Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.As of the 11th of December 2024, Sales General And Administrative To Revenue is likely to grow to 17.94, while Selling General Administrative is likely to drop about 31.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 153.6M | 157.1M | 127.6M | 82.0M | Cost Of Revenue | 4.6M | 6.5M | 5.6M | 5.4M |
Adverum Biotechnologies fundamental ratios Correlations
Click cells to compare fundamentals
Adverum Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adverum Biotechnologies fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 222.7M | 482.6M | 439.7M | 308.4M | 173.0M | 247.9M | |
Short Long Term Debt Total | 32.2M | 30.7M | 103.0M | 106.8M | 75.0M | 48.0M | |
Other Current Liab | 2.6M | 9.1M | 14.8M | 3.3M | 2.1M | 3.9M | |
Total Current Liabilities | 19.4M | 20.9M | 21.3M | 32.2M | 24.9M | 15.0M | |
Total Stockholder Equity | 175.0M | 434.3M | 316.2M | 181.5M | 83.5M | 79.3M | |
Other Liab | 1.4M | 48K | 1.1M | 1.0M | 942.3K | 895.2K | |
Property Plant And Equipment Net | 45.8M | 47.1M | 119.1M | 113.9M | 67.0M | 37.4M | |
Net Debt | (33.6M) | (31.7M) | 68.8M | 38.4M | 36K | 37.8K | |
Retained Earnings | (385.0M) | (502.5M) | (648.1M) | (802.6M) | (919.8M) | (873.8M) | |
Accounts Payable | 4.1M | 2.8M | 1.4M | 2.2M | 1.9M | 1.9M | |
Cash | 65.9M | 62.4M | 34.2M | 68.4M | 75M | 78.2M | |
Non Current Assets Total | 46.9M | 48.1M | 122.6M | 117.8M | 70.2M | 39.7M | |
Cash And Short Term Investments | 166.0M | 429.7M | 305.2M | 185.6M | 96.5M | 91.7M | |
Common Stock Shares Outstanding | 6.4M | 8.5M | 9.8M | 9.9M | 10.1M | 18.4M | |
Liabilities And Stockholders Equity | 222.7M | 482.6M | 439.7M | 308.4M | 173.0M | 247.9M | |
Non Current Liabilities Total | 28.4M | 27.3M | 102.2M | 94.6M | 64.6M | 67.9M | |
Other Current Assets | 9.8M | 9.4M | 6.2M | 5.0M | 6.2M | 4.4M | |
Other Stockholder Equity | 560.7M | 937.1M | 965.0M | 985.7M | 1.0B | 567.3M | |
Total Liab | 47.8M | 48.2M | 123.5M | 126.9M | 89.5M | 46.9M | |
Property Plant And Equipment Gross | 24.9M | 47.1M | 132.2M | 130.9M | 81.5M | 85.6M | |
Total Current Assets | 175.9M | 434.4M | 317.1M | 190.6M | 102.8M | 97.6M | |
Accumulated Other Comprehensive Income | (725K) | (261K) | (714K) | (1.5M) | (473K) | (496.7K) | |
Property Plant Equipment | 24.9M | 27.7M | 33.1M | 113.9M | 130.9M | 137.5M | |
Non Currrent Assets Other | 11K | 29K | 250K | 1.4M | 1.2M | 1.3M | |
Other Assets | 1.0M | 1.0M | 3.5M | 3.9M | 4.5M | 4.7M | |
Net Tangible Assets | 175.0M | 434.3M | 316.2M | 181.5M | 208.7M | 256.7M | |
Current Deferred Revenue | 8.6M | 12.3M | 16.0M | (6.1M) | (7.0M) | (6.7M) | |
Common Stock Total Equity | 5K | 6K | 7K | 10K | 11.5K | 6.5K | |
Retained Earnings Total Equity | (320.5M) | (385.0M) | (502.5M) | (648.1M) | (583.3M) | (554.1M) | |
Short Term Investments | 100.1M | 367.3M | 271.0M | 117.2M | 21.5M | 20.4M | |
Capital Surpluse | 522.5M | 560.7M | 937.1M | 965.0M | 1.1B | 599.6M | |
Short Term Debt | 4.0M | 8.9M | 3.8M | 26.5M | 20.8M | 21.9M | |
Common Stock | 5K | 6K | 7K | 10K | 11.5K | 7.4K | |
Non Current Liabilities Other | 28.4M | 27.3M | 102.2M | 1.0M | 1.2M | 1.1M | |
Net Invested Capital | 175.0M | 434.3M | 316.2M | 181.5M | 83.5M | 79.3M | |
Net Working Capital | 156.5M | 413.6M | 295.8M | 158.3M | 77.9M | 74.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share 0.059 | Quarterly Revenue Growth (0.70) | Return On Assets (0.30) | Return On Equity (0.76) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.